WO2024176192 - IMMUNOGENIC COMPOSITIONS
National phase entry is expected:
Publication Number
WO/2024/176192
Publication Date
29.08.2024
International Application No.
PCT/IB2024/051778
International Filing Date
23.02.2024
Title **
[English]
IMMUNOGENIC COMPOSITIONS
[French]
COMPOSITIONS IMMUNOGÈNES
Applicants **
BIONTECH SE
An der Goldgrube 12
55131 Mainz, DE
Inventors
SAHIN, Ugur
c/o BioNTech SE
An der Goldgrube 12
55131 Mainz, DE
MUIK, Alexander
c/o BioNTech SE
An der Goldgrube 12
55131 Mainz, DE
VOGEL, Annette
c/o BioNTech SE
An der Goldgrube 12
55131 Mainz, DE
CADIMA COUTO, Carla Iris
c/o BioNTech SE
An der Goldgrube 12
55131 Mainz, DE
LUI, Bonny Gaby
c/o BioNTech SE
An der Goldgrube 12
55131 Mainz, DE
QUANDT, Jasmin
c/o BioNTech SE
An der Goldgrube 12
55131 Mainz, DE
Priority Data
63/448,243
24.02.2023
US
63/448,244
24.02.2023
US
63/486,953
24.02.2023
US
63/486,958
24.02.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 8186 | |
| EPO | Filing, Examination | 58338 | |
| Japan | Filing | 592 | |
| South Korea | Filing | 673 | |
| USA | Filing, Examination | 20235 |
Total: 88024 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) for use in treating and/or preventing various infectious agents. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and/or overcome immune imprinting in various infectious diseases.[French]
L'invention concerne des compositions comprenant des antigènes protéiques et de l'ARN codant pour celles-ci (par exemple, des compositions comprenant des antigènes protéiques et des antigènes codant pour l'ARN) destinées à être utilisées dans le traitement et/ou la prévention de divers agents infectieux. L'invention concerne également des compositions immunogènes et des préparations médicales les comprenant, ainsi que des procédés de fabrication et d'utilisation de celles-ci. Dans certains modes de réalisation, les technologies de l'invention peuvent être utilisées pour traiter et/ou surmonter l'empreinte immunitaire dans diverses maladies infectieuses.